Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Ipilimumab MeSH Descriptor Data 2025


MeSH Heading
Ipilimumab
Tree Number(s)
D12.776.124.486.485.114.224.060.798
D12.776.124.790.651.114.224.060.798
D12.776.377.715.548.114.224.200.798
Unique ID
D000074324
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000074324
Scope Note
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
Entry Term(s)
Anti-CTLA-4 MAb Ipilimumab
MDX 010
MDX-010
MDX-CTLA-4
MDX010
Yervoy
Pharm Action
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Registry Numbers
0
Related Numbers
6T8C155666
See Also
CTLA-4 Antigen
Public MeSH Note
2018; IPILIMUMAB was indexed under ANTIBODIES, MONOCLONAL, 2012-2017
History Note
2018(2012)
Date Established
2018/01/01
Date of Entry
2017/07/11
Revision Date
2020/02/28
Ipilimumab Preferred
MDX 010 Narrower
MDX-CTLA-4 Narrower
Yervoy Narrower
page delivered in 0.127s